- October 28, 2013
- October 17, 2013
On October 15, 2013, Innate Pharma (IPH.PA) presented a new proprietary technology for generating antibody-drug conjugates (ADCs) at the World ADC Summit in San Francisco.
The technology represents an opportunity for Innate to expand its portfolio of developmental candidatesor form strategic partnerships with leading companies.
- September 30, 2013
With very promising clinical results in oncology, immunotherapy is back at the front of the international scene. In France projects come out on the academic and industrial side.
In France several companies of biotechnology are already positioned in immunotherapy with, at the head, Transgene and Innate Pharma, whose results of products under development are expected impatiently
Article Monthly Pharmaceutiques September 2013 - Anne Pezet
- September 13, 2013
- September 20, 2013
- July 2, 2013
- June 24, 2013
Innate Pharma’s Programs Target the Next Generation of Cancer Treatment
The 2013 ASCO conference highlighted some exciting cancer therapies that target the immune system, an approach where Innate is well positioned to be a leader. Immunotherapies as single agent treatments have demonstrated benefits for patients, and that potential may be further expanded through the use of combination treatments, such as targeting both the innate and adaptive immune systems.
To view the report, please visit LSA’s website
- June 7, 2013
Ces traitements pourraient générer un chiffre d’affaires de 35 milliards de dollars d’ici à cinq ans. BMS occupe une position de leader sur ce marché, devant Roche, Merck et AstraZeneca...
Encadré en fin d'article sur le "très prometteur lirilumab"
- June 1, 2013
Immuno-oncology in the Wall Street Journal headlines.
- May 31, 2013
Just a few years ago, nobody believed it was possible to harness the immune system to respond to cancer, but drugs like nivolumab, the experimental Bristol-Myers drug Tartaglia receives, are showing promise, even in some patients who have never tried any other treatments.